Venture Capital Investors

Sanderling Ventures

venture capital firm Sanderling Ventures backs promising high-tech companies.

Venture Investor Overview

Venture Investor
Sanderling Ventures
Status
InActive
Investor Type
Venture Capital
Activity Level
137 transactions
Funds Raised
Unknown
Industry Focus
Biopharmaceutical

Contact Information

Contact
Fred Middleton
Title
Managing Director
Mailing Address
400 South El Camino Real 1200
San Mateo, CA 94402
USA
Phone
(650) 401-2000
Website
www.sanderling.com
Email Address
[email protected]

Background Information

Overview
Founded in 1979, Sanderling is among the oldest investment firms dedicated to building new biomedical companies. Sanderling demonstrates that significant companies are best built in close working partnerships with entrepreneurs. Sanderling's unique approach combines a specialized investment focus with active management and long-term commitment to ensure the highest rates-of-return for both its entrepreneurs and investors.
Profile
Sanderling Ventures LinkedIn Company Profile
Social Media
Sanderling Ventures Company Twitter Account
Company News
Sanderling Ventures News
Facebook
Sanderling Ventures on Facebook
YouTube
Sanderling Ventures on YouTube
Last Transaction
6/24/2021

Transaction History

Our records indicate that Sanderling Ventures invested in the VC transactions listed below. Dollar amounts are for the entire raise, which may include other investors.

Company
Date
Amount
Glycomine
6/24/2021
$68,000,000
CalciMedica
3/12/2021
$21,000,000
CalciMedica
5/25/2020
$15,000,000
Glycomine
8/8/2019
$33,000,000
ViaCyte
11/30/2018
$80,000,000
Metavention
1/9/2018
$65,000,000
SpecificiT
9/12/2017
Unknown
PreciThera
7/28/2017
$29,000,000
Glycomine
11/17/2016
$12,000,000
Torax Medical
8/8/2016
$25,000,000
DalCor Pharmaceuticals
4/20/2016
$150,000,000
Axikin Pharmaceuticals
6/30/2015
$1,500,000
Altor Bioscience
6/30/2015
$10,715,000
TheraVida
3/31/2015
$300,000
CalciMedica
3/31/2015
$3,000,000
Lineagen
12/18/2013
$3,500,000
ViaCyte
7/10/2013
$10,600,000
Sotera Wireless
2/6/2013
$14,800,000
Torax Medical
9/19/2012
$30,000,000
TheraVida
6/30/2012
$1,000,000
TheraVida
12/31/2011
$800,000
Sotera Wireless
12/15/2011
$12,200,000
Axikin Pharmaceuticals
9/30/2011
$3,500,000
InfraReDx
9/30/2011
$50,000
TheraVida
9/30/2011
$1,300,000
InfraReDx
3/31/2011
$502,000
TheraVida
3/31/2011
$1,300,000
Axikin Pharmaceuticals
3/31/2011
$2,500,000
Axikin Pharmaceuticals
12/31/2010
$2,967,000
InfraReDx
10/12/2010
$21,000,000
Axikin Pharmaceuticals
9/30/2010
$1,000,000
Pulsar Vascular
9/30/2010
$1,121,000
Altor Bioscience
9/30/2010
$1,375,000
Cylene Pharmaceuticals
9/27/2010
$12,000,000
Taligen Therapeutics
8/23/2010
$10,000,000
Gemin X Pharmaceuticals
8/5/2010
$8,000,000
Lineagen
6/30/2010
$5,012,000
Altor Bioscience
6/30/2010
$250,000
Gemin X Pharmaceuticals
4/22/2010
$16,000,000
Sotera Wireless
4/20/2010
$10,750,000
NeoMend
1/27/2010
$30,000,000
Altor Bioscience
12/31/2009
$1,209,000
Axikin Pharmaceuticals
12/31/2009
$2,100,000
CalciMedica
12/15/2009
$12,000,000
Endocyte
10/18/2009
$26,000,000
InfraReDx
9/30/2009
$11,061,000
Asteres
9/30/2009
$4,250,000
Chimerix
8/11/2009
$16,000,000
NovoStent
6/30/2009
$1,056,000
Triage Wireless
6/30/2009
$2,400,000
Axikin Pharmaceuticals
6/30/2009
$1,500,000
Taligen Therapeutics
5/12/2009
$26,000,000
TheraVida
3/31/2009
$83,200
TRF Pharma
3/31/2009
$6,000,000
Axikin Pharmaceuticals
1/22/2009
$3,000,000
Pacira Pharmaceuticals
12/31/2008
$55,000,000
Asteres
12/31/2008
$5,000,000
CalciMedica
12/17/2008
$4,000,000
NovoStent
9/30/2008
$10,800,000
Gemin X Pharmaceuticals
7/1/2008
$38,000,000
REN Pharmaceuticals
6/30/2008
$1,500,000
CoMentis
6/30/2008
$20,000,000
Axikin Pharmaceuticals
6/30/2008
$2,050,000
Torax Medical
6/30/2008
$3,164,000
Asteres
6/30/2008
$4,000,000
Actimis Pharmaceuticals
6/30/2008
$9,600,000
TheraVida
6/30/2008
$60,000
Pacira Pharmaceuticals
3/31/2008
$14,999,900
Naviscan PET Systems
3/31/2008
$4,000,000
TheraVida
3/31/2008
$700,000
Triage Wireless
3/31/2008
$20,300,000
Taligen Therapeutics
2/1/2008
$65,000,000
InfraReDx
12/31/2007
$15,600,000
Pulsar Vascular
12/31/2007
$1,908,000
Triage Wireless
12/31/2007
$500,000
CoMentis
12/31/2007
$12,000,000
Lineagen
12/6/2007
$5,780,000
Asteres
11/1/2007
$4,000,000
TRF Technologies
9/30/2007
$6,000,000
REN Pharmaceuticals
9/30/2007
$1,000,000
CoMentis
9/30/2007
$15,000,000
Xytis
9/30/2007
$7,500,000
ViaCyte
7/16/2007
$25,000,000
TheraVida
7/5/2007
Unknown
NeoMend
6/30/2007
$10,025,000
NovoStent
6/30/2007
$5,200,000
Naviscan PET Systems
5/4/2007
$15,000,000
Harkness Pharmaceuticals
3/31/2007
$1,000,000
ReGen Biologics
3/31/2007
$3,000,000
CoMentis
3/31/2007
$12,000,000
InfraReDx
3/31/2007
$2,020,000
Endocyte
3/23/2007
$15,000,000
Chimerix
2/23/2007
$23,100,000
Cylene Pharmaceuticals
1/24/2007
$44,000,000
Dynatherm Medical
12/31/2006
$2,370,000
ReGen Biologics
12/31/2006
$5,000,000
REN Pharmaceuticals
12/31/2006
$1,050,000
Taligen Therapeutics
9/30/2006
$2,800,000
Trinity Biosystems
9/30/2006
$1,500,000
TRF Technologies
9/30/2006
$2,000,000
Chimerix
9/30/2006
$5,500,000
CoMentis
9/28/2006
$50,000,000
Alteer
6/30/2006
$25,100,000
ViaCyte
6/30/2006
$14,233,000
Trinity Biosystems
6/30/2006
$21,000,000
Tomophase
6/30/2006
$1,000,000
Artielle ImmunoTherapeutics
6/28/2006
$11,000,000
Pulsar Vascular
3/31/2006
$600,000
Triage Wireless
3/31/2006
$1,000,000
Asteres
3/31/2006
$5,000,000
Harkness Pharmaceuticals
3/31/2006
$1,600,000
CoMentis
3/31/2006
$2,999,000
Theregen
1/17/2006
$1,500,000
Xytis
1/9/2006
$24,500,000
Naviscan PET Systems
11/28/2005
$6,500,000
Tomophase
11/23/2005
$4,500,000
Asteres
9/30/2005
$2,000,000
CoMentis
9/19/2005
$5,690,000
NovoStent
8/17/2005
$12,750,000
Triage Wireless
8/15/2005
$3,000,000
Alteer
8/11/2005
$16,500,000
Zapaq
6/30/2005
$2,350,000
InfraReDx
6/30/2005
$2,803,000
Torax Medical
6/28/2005
$10,000,000
Gemin X Pharmaceuticals
5/19/2005
$50,000,000
Actimis Pharmaceuticals
4/28/2005
$6,000,000
CareCentric
3/31/2005
$250,000
ViaCyte
3/31/2005
$1,575,000
Zapaq
3/31/2005
$400,000
NeoMend
3/31/2005
$150,000
Endocyte
12/6/2004
$23,000,000
Chimerix
11/4/2004
$11,000,000
Virogenomics
6/28/2004
$11,000,000
Favrille
4/6/2004
$44,000,000
Kadmus Pharmaceuticals
2/10/2004
$15,300,000
Asteres
9/23/2003
Unknown
Endocyte
8/15/2003
$15,000,000

 

Investor Contacts

Title
Name
Email & Social
Partner
Pierre Beauparlant
  Pierre Beauparlant LinkedIn Profile  Pierre Beauparlant Twitter Account  Pierre Beauparlant News  Pierre Beauparlant on Facebook
Managing Director
Michael Dixon
  Michael Dixon LinkedIn Profile  Michael Dixon Twitter Account  Michael Dixon News  Michael Dixon on Facebook
Partner
Benjamin McGraw
  Benjamin McGraw LinkedIn Profile  Benjamin McGraw Twitter Account  Benjamin McGraw News  Benjamin McGraw on Facebook
Managing Director
Robert McNeil
  Robert McNeil LinkedIn Profile  Robert McNeil Twitter Account  Robert McNeil News  Robert McNeil on Facebook
Managing Director
Peter McWilliams
  Peter McWilliams LinkedIn Profile  Peter McWilliams Twitter Account  Peter McWilliams News  Peter McWilliams on Facebook
Managing Director
Fred Middleton
  Fred Middleton LinkedIn Profile  Fred Middleton Twitter Account  Fred Middleton News  Fred Middleton on Facebook
Managing Director
Timothy Mills
  Timothy Mills LinkedIn Profile  Timothy Mills Twitter Account  Timothy Mills News  Timothy Mills on Facebook
Managing Director
Timothy Wollaeger
  Timothy Wollaeger LinkedIn Profile  Timothy Wollaeger Twitter Account  Timothy Wollaeger News  Timothy Wollaeger on Facebook

 

Funds

No fund closings have been recorded for this company.

 

Portfolio Companies

Sanderling Ventures has invested in the companies below, according to our database records. If we are missing a portfolio company, please let us know.

Tech Company
Actimis Pharmaceuticals
Alteer
Altor Bioscience
Artielle ImmunoTherapeutics
Asteres
Axikin Pharmaceuticals
CalciMedica
CareCentric
Chimerix
CoMentis
Cylene Pharmaceuticals
DalCor Pharmaceuticals
Dynatherm Medical
Endocyte
Favrille
Gemin X Pharmaceuticals
Glycomine
Harkness Pharmaceuticals
InfraReDx
Kadmus Pharmaceuticals
Lineagen
Metavention
Naviscan PET Systems
NeoMend
NovoStent
Pacira Pharmaceuticals
PreciThera
Pulsar Vascular
ReGen Biologics
REN Pharmaceuticals
Sotera Wireless
SpecificiT
Taligen Therapeutics
TheraVida
Theregen
Tomophase
Torax Medical
TRF Pharma
TRF Technologies
Triage Wireless
Trinity Biosystems
ViaCyte
Virogenomics
Xytis
Zapaq

 

 

 

 

Browse more venture capital investors:

Sandbrook Capital | Sandhill Angels

 

Share this article

 

About Our VC Investor Database

This VC firm profile is powered by VentureDeal.com, a leading supplier of venture capital funding data.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.